Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy

Abdullah, Samaa; Aldahlawi, AliaM

doi:10.4103/jmau.jmau_20_21

Cited by 6 publications

(5 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFN-DCs stimulate CD4 + and CD8 + T-cell-mediated immune responses against malignant antigen-1 in CRC patients at various phases [109]. Based on our extensive preclinical and clinical evidence of IFN-DC, these DCs are important autologous cellular resources for improving advanced DC agents for CRC clinical trials [111]. DC-based therapy could treat CRC patients with autologous DCs.…”

Section: Dcs Utilization In Crc Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Interaction between Gut Microbiota and Dendritic Cells in Colorectal Cancer

Zaher,

Basingab

2023

Biomedicines

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a malignancy that manifests in serial stages and has been observed to have an escalating incidence in modern societies, causing a significant global health problem. The development of CRC is influenced by various exogenous factors, including lifestyle, diet, nutrition, environment, and microbiota, that can affect host cells, including immune cells. Various immune dysfunctions have been recognized in patients with CRC at different stages of this disease. The signature of microbiota in the development of CRC—inflammation related to obesity, diet, and reactive host cells, such as dendritic cells (DCs)—has been highlighted by many studies. This study focuses on DCs, the primary cellular mediators linking innate and adaptive immune responses against cancer. In addition, this review focuses on the role of microbiota in dysbiosis and how it affects DCs and, in turn, the immune response and progression of CRC by stimulating different sets of T cells. Additionally, DCs’ role in protecting this delicate balance is examined. This is to determine how gene yields of commensal microbiota may be critical in restoring this balance when disrupted. The stages of the disease and major checkpoints are discussed, as well as the role of the C-type lectin receptor of immature DCs pattern recognition receptor in CRC. Finally, based on a thorough examination of worldwide clinical studies and recent advancements in cancer immunotherapy, it is recommended that innovative approaches that integrate DC vaccination strategies with checkpoint inhibitors be considered. This approach holds great promise for improving CRC management.

show abstract

Section: Dcs Utilization In Crc Immunotherapymentioning

confidence: 99%

“…agents for CRC clinical trials [111]. DC-based therapy could treat CRC patients with autologous DCs.…”

Section: Dcs Utilization In Crc Immunotherapymentioning

confidence: 99%

Interaction between Gut Microbiota and Dendritic Cells in Colorectal Cancer

Zaher,

Basingab

2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Moreover, the inflammation role was to activate the adaptive immune cells by activating the innate system's antigen-presenting cells, such as dendritic cells. Additionally, natural killer (NK) cells and macrophages of the innate system help capturing the cancer cells and releasing immunostimulatory cytokines to activate the adaptive system [25].…”

Section: The Influence Of the Host's Immune Responses On Colon Cancer...mentioning

confidence: 99%

“…The VEGF amplifies the vasculature, the proinflammatory status, and the wound healing environment around the cancerous tissue. As a result, this can promote the cancer growth, metastasis, and activation of the tumor-associated macrophages to escape the immune surveillance for cancerous tissue [22,25,34].…”

Section: Author Detailsmentioning

confidence: 99%

Colorectal Cancer Stages, Progress, Genetic Predisposition, and Immune Surveillance

Abdullah¹

2022

Recent Understanding of Colorectal Cancer Treatment

View full text Add to dashboard Cite

Colon cancer (CC) is highly malignant and is considered the second cause of death worldwide. However, the overall CC survival rate is improving due to the rapid development of screening tools and improved treatment options. This raised the need to develop effective approaches for medical intervention. Moreover, CC is classified into four stages: stages I, II, III, and IV. On the other hand, the driver genes played vital regulatory roles in essential pathways for cellular division, cell survival, fate, and genome stability. For example, the RAS mitogen-activated protein kinase is essential for cellular division. Additionally, carcinogenesis is linked to the mutations, which are reported in the Kirsten rat sarcoma viral oncogene homolog gene, Adenomatous Polyposis Coli gene, Tumor Protein 53 gene, and SMAD family member 4 genes, Mothers against decapentaplegic homolog 4 gene. In addition, the immune system reactions have different impacts on CC growth and management. The inflammation process is described as one of the innate responses. The inflammation process is initiated and exacerbated by various types of immune cells included the macrophages, and neutrophils for their activation, margination, extravasation, and migration to the damaged tissue. The preferred role of inflammation against cancer is at stages I and II.

show abstract

“…Immunotherapy includes various treatments based on antibodies and T cell transfer; these are among the most critical cells used in CRC immunotherapy, and they are used in three ways, expanded without any change, TCR genetic manipulation, and CAR-T cell application ( 16 ). Also, dendritic cells (DCs) can be used to treat various tumors ( 17 ). Antibodies (Ab) used in the treatment of tumors target multiple pathways of tumor progression, including angiogenesis, tumor growth, metastasis, and immune suppression mechanisms, which have been very promising ( 18 , 19 ).…”

Section: Introductionmentioning

confidence: 99%

Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment

He,

Lan,

Jin

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

As one of the main threats to human life (the fourth most dangerous and prevalent cancer), colorectal cancer affects many people yearly, decreases patients’ quality of life, and causes irreparable financial and social damages. In addition, this type of cancer can metastasize and involve the liver in advanced stages. However, current treatments can’t completely eradicate this disease. Chemotherapy and subsequent surgery can be mentioned among the current main treatments for this disease. Chemotherapy has many side effects, and regarding the treatment of this type of tumor, chemotherapy can lead to liver damage, such as steatohepatitis, steatosis, and sinus damage. These damages can eventually lead to liver failure and loss of its functions. Therefore, it seems that other treatments can be used in addition to chemotherapy to increase its efficiency and reduce its side effects. Biological therapies and immunotherapy are one of the leading suggestions for combined treatment. Antibodies (immune checkpoint blockers) and cell therapy (DC and CAR-T cells) are among the immune system-based treatments used to treat tumors. Immunotherapy targets various aspects of the tumor that may lead to 1) the recruitment of immune cells, 2) increasing the immunogenicity of tumor cells, and 3) leading to the elimination of inhibitory mechanisms established by the tumor. Therefore, immunotherapy can be used as a complementary treatment along with chemotherapy. This review will discuss different chemotherapy and immunotherapy methods for colorectal cancer. Then we will talk about the studies that have dealt with combined treatment.

show abstract

Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy

Cited by 6 publications

References 61 publications

Interaction between Gut Microbiota and Dendritic Cells in Colorectal Cancer

Interaction between Gut Microbiota and Dendritic Cells in Colorectal Cancer

Colorectal Cancer Stages, Progress, Genetic Predisposition, and Immune Surveillance

Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment

Contact Info

Product

Resources

About